32 results about "Pleurodesis" patented technology

An accelerated two-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease. The first phase includes creation of a localized pleurodesis. The localized pleurodesis is created using chemical agents and/or mechanical fasteners to secure the visceral membrane to the pleural membrane. The second phase includes introduction of a surgical instrument into the lung via the pleurodesis to create the pneumostoma. The first and second phases are performed as parts of a single surgical procedure. The formation of a stable pleurodesis is to prevent pneumothorax during the procedure.

A percutaneous single-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease. A pneumostomy instrument is introduced percutaneously through the thoracic wall, parietal membrane, visceral membrane and into the parenchymal tissue of the lung. The pneumostomy instrument crosses the pleural cavity between the parietal membrane and visceral membrane there being no pleurodesis between the membranes prior to passage of the pneumostomy instrument. A pneumoplasty device at the distal end of the pneumostomy instrument displaces and engages the parenchymal tissue of the lung and the pneumostomy instrument is used to secure the lung and visceral membrane in contact with the parietal membrane and chest wall. The pneumostomy instrument is left in place while a pneumostoma tract heals and pleurodesis occurs between the pleural membranes surrounding the pneumostomy instrument.

A two-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease The first phase is a procedure to induce creation of a localized pleurodesis and is preferably performed as an outpatient procedure. The second phase is a procedure to introduce a surgical instrument into the lung via the pleurodesis to create the pneumostoma. An interval of about one of more days between the first and second phases allows the formation of a stable pleurodesis to prevent pneumothorax during the procedure.

Methods and systems for treating pleural disease comprising a providing a low dosage of a sclerosing agent over a period of time. Certain examples include catheter with a sclerosing agent that is inserted into the pleural space. The sclerosing agent is released in a sustained-release manner over a period of time to achieve diffuse pleurodesis of the pleural layers.

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

The invention provides methods and devices for creating a localized pleurodesis between the thoracic wall and the lung such that a ventilation bypass conduit may be introduced into the lung through the thoracic wall and visceral membrane without causing a pneumothorax. A medical device such as a catheter is used to enter the pleural cavity and deliver a pleurodesis agent to a localized area between the visceral and parietal membranes.

The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

Tissue adhesions using surgical adjuncts and medicants are provided. In general, an implantable adjunct can have one or more medicants releasably retained therein that are configured to induce tissueadhesions. The adjunct can be configured to be applied to lung tissue in conjunction with surgical staples using a surgical stapler. Pleurodesis can be encouraged through delivery of the adjunct to the lung tissue.

The invention discloses a special talcum powder spraying device for pleurodesis. The special talcum powder spraying device comprises a talcum powder spraying cavity, one end of the talcum powder spraying cavity is connected with a first connection hose, one end of the first connection hose is fixedly connected with one end of a second connection hose, and the first connection hose is provided withan adhesive tape. The other end of the second connection hose is connected with one side of a nozzle, the other side of the nozzle is provided with spraying holes distributed at equal intervals, anda small air pump is fixedly mounted on the outer wall of the talcum powder spraying cavity. A piston rod is fixedly connected with one side of a push block which is arranged in a talcum powder storagebox, one end of the piston rod is connected with the small air pump at the outer end, the small air pump drives the piston rod to move to drive the push block to move towards one side, and thus, talcum powder is pushed into the first connection hose, automatic powder treatment is realized, and the problem of low efficiency caused by manual operation is avoided.